Systemic corticosteroids are used during acute exacerbations and for individuals with poorly controlled end-stage COPD despite being optimally medically managed. All COPD patients who have ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for ...

AstraZeneca’s respiratory drug Fasenra has failed in chronic obstructive pulmonary disease (COPD), in a market hotly contested by its UK rival GlaxoSmithKline. Fasenra (benralizumab), developed ...

The early stages of the disease are largely asymptomatic; as a result, COPD is often diagnosed late ... reducing deaths related to the disease 3, and changing the underlying nature of the disease ...

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

AstraZeneca is studying Fasenra in late-stage studies for COPD. GSK has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

As Delhi’s Air quality deteriorates, Stage 1 of GRAP has been implemented. What is the purpose of GRAP? How does it help in ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...

Glycopyrrolate: Following inhaled administration of Breztri Aerosphere in subjects with COPD, Cmax occurred within 2 to 6 minutes. Steady state is estimated to be achieved after approximately 3 ...

It has launched several new drugs in the past couple of years and accelerated its mid- and late-stage pipeline this year ... obstructive pulmonary disease (COPD) — in Europe in July 2024.In ...